¿Es la obesidad un factor predictivo de falta de respuesta al tratamiento en la artritis psoriásica? Actualización de una revisión sistemática

Reumatología Clínica - Tập 17 - Trang 268-278 - 2021
Jordi Gratacós1, Eva Galíndez2, Teresa Otón3
1Servicio de Reumatología, Hospital Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell (Barcelona), España
2Servicio de Reumatología, Hospital Universitario Basurto, Bilbao, Vizcaya, España
3Instituto de Salud Musculoesquelética, Madrid, España

Tài liệu tham khảo

Husted, 2013, Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis, J Rheumatol., 40, 1349, 10.3899/jrheum.121500 Sanchez-Carazo, 2014, Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: A cross-sectional study (Arizona study), J Dermatol., 41, 673, 10.1111/1346-8138.12465 Almodovar, 2018, Development of a checklist for patients with axial spondyloarthritis and psoriatic arthritis in daily practice: ONLY TOOLS project, Reumatol Clin., 14, 155, 10.1016/j.reuma.2016.12.003 Torre-Alonso, 2017, Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain, Rheumatol Int., 37, 1239, 10.1007/s00296-017-3702-9 Husni, 2010, Managing comorbid disease in patients with psoriatic arthritis, Curr Rheumatol Rep., 12, 281, 10.1007/s11926-010-0112-3 Ogdie, 2014, Comprehensive treatment of psoriatic arthritis: Managing comorbidities and extraarticular manifestations, J Rheumatol., 41, 2315, 10.3899/jrheum.140882 Boehncke, 2013, Burden of disease: Psoriasis and psoriatic arthritis, Am J Clin Dermatol., 14, 377, 10.1007/s40257-013-0032-x Boehncke, 2014, Diagnosing and treating psoriatic arthritis: An update, Br J Dermatol., 170, 772, 10.1111/bjd.12748 Labitigan, 2014, Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis, Arthritis Care Res (Hoboken)., 66, 600, 10.1002/acr.22185 Love, 2011, Prevalence of the metabolic syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006, Arch Dermatol., 147, 419, 10.1001/archdermatol.2010.370 Wang, 2008, Psoriasis is associated with increased levels of serum leptin, Br J Dermatol., 158, 1134, 10.1111/j.1365-2133.2008.08456.x Haroon, 2014, High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease, J Rheumatol., 41, 1357, 10.3899/jrheum.140021 Bhole, 2012, Differences in body mass index among individuals with PsA, psoriasis, RA and the general population, Rheumatology (Oxford)., 51, 552, 10.1093/rheumatology/ker349 Toussirot, 2014, TNFalpha blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: A 2-year prospective study, Eur J Nutr., 53, 951, 10.1007/s00394-013-0599-2 Galíndez, 2016, Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?, Reumatol Clin., 12, 307, 10.1016/j.reuma.2015.12.005 Schmajuk, 2014, Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record, Arthritis Care Res (Hoboken)., 66, 1159, 10.1002/acr.22294 Higgins, 2011 Wells, 2014 Menter, 2016, Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR), J Eur Acad Dermatol Venereol., 30, 1148, 10.1111/jdv.13611 Kavanaugh, 2015, Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: Results from a randomized, placebo-controlled phase iii trial, Arthritis Care Res (Hoboken)., 67, 1739, 10.1002/acr.22645 Huynh, 2014, Persistence of low disease activity after tumor necrosis factor inhibitor withdrawal in patients with psoriatic arthritis, Arthritis Reumatol., 66, S704 Huynh, 2017, Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis, RMD Open., 3, e000395, 10.1136/rmdopen-2016-000395 Cassano, 2008, Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: An exploratory analysis from the APHRODITE data, J Biol Regul Homeost Agents., 22, 233 McInnes, 2017, Body mass index does not influence the efficacy of subcutaneous abatacept in patients with PSA: Results from a phase III trial, Arthritis Reumatol., 69 Mease, 2015, Therapeutic response in adalimumab-treated patients with psoriatic arthritis in relation to weight, Ann Rheum Dis, 74, 1175, 10.1136/annrheumdis-2015-eular.1339 Ritchlin, 2014, Ann Rheum Dis., 73, 990, 10.1136/annrheumdis-2013-204655 Schett, 2014, Apremilast, an oral phosphodiesterase 4 inhibitor, and the impact of baseline weight and BMI on ACR20 and HAQ-DI response: Pooled results from 3 phase 3, randomized, controlled trials, Arthritis Reumatol., 66, S689 Strober, 2008, Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis, Br J Dermatol., 159, 322, 10.1111/j.1365-2133.2008.08628.x Costa, 2014, Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: An observational study, Immunol Res., 61, 147, 10.1007/s12026-014-8595-z Eder, 2015, Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis, Ann Rheum Dis., 74, 813, 10.1136/annrheumdis-2013-204448 Haddad, 2013, The Characteristics and Predictors of Minimal Disease Activity in Patients with Psoriatic Arthritis on TNF Blockers, Ann Rheum Dis, 72 Iannone, 2012, Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-alpha therapy, Scand J Rheumatol., 42, 41, 10.3109/03009742.2012.715186 Chiricozzi, 2016, Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: Results of a single-centre, retrospective study, JEur Acad Dermatol Venereol., 31, 304, 10.1111/jdv.13771 Fornaro, 2017, Treatment patterns, survival and long-term effectiveness of biological agents in psoriatic arthritis patients, Arthritis Reumatol., 69 Elkayam, 2015, Increased body mass index and biologics drug survival in patients with inflammatory rheumatic diseases, Ann Rheum Dis., 74, 326, 10.1136/annrheumdis-2015-eular.5437 Greenberg, 2011, Effect of weight, body mass index and weight-based dosing on persistency of anti-tnfs in psoriatic arthritis, Arthritis Reumatol., 63 Højgaard, 2016, The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries, Rheumatology (Oxford)., 55, 2191, 10.1093/rheumatology/kew326 Mease, 2015, Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: Results from the Corrona registry, RMD Open., 1, e000181, 10.1136/rmdopen-2015-000181 Ogdie, 2016, Predictors of achieving remission among patients with psoriatic arthritis prescribed TNF inhibitors, Arthritis Reumatol., 68, 2160 Di Minno, 2013, Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis, Arthritis Care Res (Hoboken)., 65, 141, 10.1002/acr.21711 Brown, 2018, Association of high BMI and failure to achieve minimal disease activity in australian psoriatic arthritis patients, Intern Med J., 48, 14 Greenberg, 2016, Comparison of secukinumab vs adalimumab in a cost per responder analysis based on a matching-adjusted indirect comparison of efficacy data for the treatment of psoriatic arthritis at 48 weeks from the us perspective, Arthritis Reumatol., 68, 1578 Ficha técnica o resumen de las características del producto_Ustekinumab. Zhu, 2010, Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis, Int J Clin Pharmacol Ther., 48, 830, 10.5414/CPP48830 Sanitarios Aedmyp. FICHA TÉCNICA O RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO_Golimumab [consultado 15 Nov 2018]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/09546001/FT_09546001.html.pdf Singh, 2017, Obesity in IBD: Epidemiology, pathogenesis, disease course and treatment outcomes, Nat Rev Gastroenterol Hepatol., 14, 110, 10.1038/nrgastro.2016.181 Mostafa, 2017, Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis, J Eur Acad Dermatol Venereol., 31, 490, 10.1111/jdv.13884 Passot, 2016, The underlying inflammatory chronic disease influences infliximab pharmacokinetics, MAbs., 8, 1407, 10.1080/19420862.2016.1216741 Wade, 2015, Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease, J Clin Pharmacol., 55, 866, 10.1002/jcph.491 Hernández-Breijo, 2018, Concomitant csdmards influence clinical response to TNF inhibitors only in overweight patients with axial spondyloarthritis [abstract], Arthritis Reumatol., 70 Di Minno, 2013, Weight loss and induction of minimal disease activity in psoriatic arthritis patients starting TNF-α blockers treatment, Ann Rheum Dis., 71 Di Minno, 2014, Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor (blockers, Ann Rheum Dis., 73, 1157, 10.1136/annrheumdis-2012-202812 Renzo, 2011, Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment, Dermatol Ther., 24, 446, 10.1111/j.1529-8019.2011.01439.x Mease, 2017, Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis, Ann Rheum Dis., 76, 1550, 10.1136/annrheumdis-2016-210724 Kavanaugh, 2014, Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor, Ann Rheum Dis., 73, 1020, 10.1136/annrheumdis-2013-205056 Upala, 2015, Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: A systematic review and meta-analysis, Int J Obes (Lond)., 39, 1197, 10.1038/ijo.2015.64